Remicade behind Mitsubishi Tanabe's first-half growth
This article was originally published in Scrip
Executive Summary
Remicade (infliximab; licensed from Johnson & Johnson) was again the star performer at Japan's Mitsubishi Tanabe Pharma (MTP) in the first half to 30 September, in which sales of the TNF-targeting antibody rose by 29% to ¥29.3 billion ($364.0 million).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.